Policy / Regulatory

NMPA Proposes Optimized Process Validation Requirements for Innovative Chemical Drugs – Draft Policy Incentivizes Global Simultaneous Filing and Launch in China
NMPA

NMPA Proposes Optimized Process Validation Requirements for Innovative Chemical Drugs – Draft Policy Incentivizes Global Simultaneous Filing and Launch in China

China's National Medical Products Administration (NMPA) issued the Announcement on Further Optimizing the Requirements for Application Materials of Process Validation for Innovative Chemical Drugs (Draft for Comments), seeking public feedback…

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
FDA Mandates Safety Labeling Changes for Opioid Pain Medications and Targets 7-OH Products

FDA Mandates Safety Labeling Changes for Opioid Pain Medications and Targets 7-OH Products

China's NHSA Issues Rules for Instant Settlement of Medical Insurance Funds

China’s NHSA Issues Rules for Instant Settlement of Medical Insurance Funds

NMPA Seeks Public Feedback on Draft Regulations for Internet Drug and Medical Device Information Services
NMPA

NMPA Seeks Public Feedback on Draft Regulations for Internet Drug and Medical Device Information Services

NMPA Updates 2025 Edition of Medical Narcotic and Psychotropic Substances Catalogs
NHC (NHFPC)NMPA

NMPA Updates 2025 Edition of Medical Narcotic and Psychotropic Substances Catalogs

Show More